Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00918203 · ClinicalTrials.gov registry record · Phase 2
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT00918203 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 137 participants.
The verdict
NCT00918203, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if participants with untreated locally advanced or metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in combination with paclitaxel/carboplatin then when treated with paclitaxel/carboplatin alone.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Olaratumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2010-01 |
| Est. Completion | 2017-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00918203
The ClinicalTrials.gov registry entry for NCT00918203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00918203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00918203 about?
NCT00918203 is a clinical study titled "A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to determine if participants with untreated locally advanced or metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in combination with paclitaxel/carboplatin then when treated with paclitaxel/carboplatin alone.
What is the current status of trial NCT00918203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2010-01. Estimated completion is 2017-11-17.
What interventions are being tested in trial NCT00918203?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Olaratumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00918203?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.